| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,000,000 ) |
| | 2025 | 2025 | NANOVALENT PHARMACEUTICALS INC | 351 EVERGREEN DR | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R42CA281707 | Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | 000 | 3 | NIH | 5/1/2025 | $1,000,000 |
|
| Issue Date FY: 2024 ( Subtotal = $1,000,000 ) |
| | 2024 | 2024 | NANOVALENT PHARMACEUTICALS INC | 351 EVERGREEN DR | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R42CA281707 | Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | 001 | 2 | NIH | 7/29/2024 | $1,000,000 |
| | 2024 | 2024 | NANOVALENT PHARMACEUTICALS INC | 351 EVERGREEN DR | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R42CA281707 | Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | 002 | 2 | NIH | 8/7/2024 | $144,596 |
| | 2024 | 2023 | NANOVALENT PHARMACEUTICALS INC | 351 EVERGREEN DR | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R42CA281707 | Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | 000 | 1 | NIH | 5/2/2024 | -$144,596 |
|
| Issue Date FY: 2023 ( Subtotal = $400,000 ) |
| | 2023 | 2023 | NANOVALENT PHARMACEUTICALS INC | 351 EVERGREEN DR | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R42CA281707 | Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | 000 | 1 | NIH | 8/8/2023 | $400,000 |
| | 2023 | 2019 | NANOVALENT PHARMACEUTICALS INC | 351 EVERGREEN DR | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44GM116530 | Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | 000 | 3 | NIH | 10/27/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | NANOVALENT PHARMACEUTICALS, INC. | 351 EVERGREEN DR STE B | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44GM116530 | Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | 000 | 3 | NIH | 8/20/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $892,769 ) |
| | 2020 | 2020 | NANOVALENT PHARMACEUTICALS, INC. | 351 EVERGREEN DR STE B | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44CA233128 | NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | 001 | 3 | NIH | 9/9/2020 | $790 |
| | 2020 | 2020 | NANOVALENT PHARMACEUTICALS, INC. | 351 EVERGREEN DR STE B | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44CA233128 | NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | 000 | 3 | NIH | 4/2/2020 | $891,979 |
| | 2020 | 2019 | NANOVALENT PHARMACEUTICALS, INC. | 351 EVERGREEN DR STE B | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44GM116530 | Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | 000 | 3 | NIH | 10/29/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,778,544 ) |
| | 2019 | 2019 | NANOVALENT PHARMACEUTICALS, INC. | 351 EVERGREEN DR STE B | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44CA233128 | NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | 001 | 2 | NIH | 4/19/2019 | $1,019,254 |
| | 2019 | 2019 | NANOVALENT PHARMACEUTICALS, INC. | 351 EVERGREEN DR STE B | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44GM116530 | Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | 001 | 3 | NIH | 8/28/2019 | $759,290 |
| | 2019 | 2018 | NANOVALENT PHARMACEUTICALS, INC. | 910 TECHNOLOGY BLVD STE G | BOZEMAN | MT | 59718-4012 | GALLATIN | USA | R44GM116530 | Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | 000 | 2 | NIH | 12/21/2018 | $0 |
| | 2019 | 2018 | NANOVALENT PHARMACEUTICALS, INC. | 351 EVERGREEN DR STE B | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44CA233128 | NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | 000 | 1 | NIH | 4/19/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,071,939 ) |
| | 2018 | 2018 | NANOVALENT PHARMACEUTICALS, INC. | 910 TECHNOLOGY BLVD STE G | BOZEMAN | MT | 59718-4012 | GALLATIN | USA | R44CA233128 | NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy | 000 | 1 | NIH | 9/14/2018 | $240,749 |
| | 2018 | 2018 | NANOVALENT PHARMACEUTICALS, INC. | 910 TECHNOLOGY BLVD STE G | BOZEMAN | MT | 59718-4012 | GALLATIN | USA | R44GM116530 | Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions | 000 | 2 | NIH | 8/29/2018 | $831,190 |
| | 2018 | 2016 | NANOVALENT PHARMACEUTICALS, INC. | 910 TECHNOLOGY BLVD STE G | BOZEMAN | MT | 59718-4012 | GALLATIN | USA | R41CA203457 | Nanoparticle Delivery System for Ewing Sarcoma Treatment | 000 | 1 | NIH | 7/6/2018 | $0 |
| | 2018 | 2016 | NANOVALENT PHARMACEUTICALS, INC. | 910 TECHNOLOGY BLVD STE G | BOZEMAN | MT | 59718-4012 | GALLATIN | USA | R41GM116530 | Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions | 000 | 1 | NIH | 7/12/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $479,478 ) |
| | 2016 | 2016 | NANOVALENT PHARMACEUTICALS, INC | 910 TECHNOLOGY BLVD STE G | BOZEMAN | MT | 59718-4012 | GALLATIN | USA | R41GM116530 | Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions | 000 | 1 | NIH | 1/21/2016 | $238,728 |
| | 2016 | 2016 | NANOVALENT PHARMACEUTICALS, INC | 910 TECHNOLOGY BLVD STE G | BOZEMAN | MT | 59718-4012 | GALLATIN | USA | R41CA203457 | Nanoparticle Delivery System for Ewing Sarcoma Treatment | 000 | 1 | NIH | 4/15/2016 | $240,750 |
|
|
